Phio PharmaceuticalsPHIO -0.97%28 PB Ratio is 0.72 as of Jul. 10, 2026, which is 227% above its 10-year median of 0.22. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Phio Pharmaceuticals ranks better than 89.65% on this metric.
Phio Pharmaceuticals Corp stock PB Ratio (=0.73) is close to 5-year high of 0.73.
The historical rank and industry rank for Phio Pharmaceuticals's PB Ratio or its related term are showing as below:
PHIO'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.22 Max: 3.59
Current: 0.72
During the past 13 years, Phio Pharmaceuticals's highest PB Ratio was 3.59. The lowest was 0.01. And the median was 0.22.
PHIO's PB Ratio is ranked better than 89.65% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs PHIO: 0.72
During the past 12 months, Phio Pharmaceuticals's average Book Value Per Share Growth Rate was -44.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -72.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -66.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Phio Pharmaceuticals was -55.30% per year. The lowest was -75.00% per year. And the median was -66.20% per year.
Back to Basics: PB Ratio
Phio Pharmaceuticals (NAS:PHIO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Phio Pharmaceuticals PB Ratio Related Terms
Phio Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phio Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Phio Pharmaceuticals (PHIO) has a PB Ratio of 0.72 as of Jul. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Phio Pharmaceuticals and its competitors. This is 227% above median its historical median of 0.22. Over the past decade, Phio Pharmaceuticals' PB Ratio has ranged from 0.01 to 3.59. According to the industry distribution chart, Phio Pharmaceuticals ranks #127 out of 1227 companies in the Biotechnology industry, placing it in the top 10.4%.
Is Phio Pharmaceuticals' PB Ratio too high?
Phio Pharmaceuticals' current PB Ratio of 0.72 is 227% above median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.59. The Biotechnology industry median PB Ratio is 2.95. Phio Pharmaceuticals' value of 0.72 is 75.6% below this industry median. Based on the distribution chart, Phio Pharmaceuticals ranks #127 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' PB Ratio compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #127 out of 1227 companies for PB Ratio. This places Phio Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Phio Pharmaceuticals' value of 0.72 is 75.6% below this benchmark. Historically, Phio Pharmaceuticals' own PB Ratio has ranged from 0.01 to 3.59 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 2.95, Phio Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phio Pharmaceuticals's current PB Ratio of 0.72 is 75.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Phio Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phio Pharmaceuticals's current PB Ratio is 0.72, which is 227% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current PB Ratio of 0.72. The current PB Ratio is 0.72, which is 227% above median its 10-year median of 0.22 and 75.6% below the Biotechnology industry median of 2.95. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current PB Ratio is 0.72 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
